Lumosa Therapeutics Co (ROCO:6535) Moat Score: 0/10 (As of Jul. 12, 2026)


ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$100.50
GF Value NT$131.19
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Moat Score?

Lumosa Therapeutics Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Lumosa Therapeutics Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lumosa Therapeutics Co might have No Moat - No discernible moat.

Lumosa Therapeutics Co  (ROCO:6535) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lumosa Therapeutics Co Moat Score Related Terms

ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$100.50 is trading 23.4% below its estimated GF Value™ of NT$131.19. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • Moat Score: 0
  • GF Value™: NT$131.19 vs. price of NT$100.50 (23.4% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$100.50
Price
NT$131.19
GF Value